Join the club for FREE to access the whole archive and other member benefits.

LIfT BioSciences cell therapy infiltrates pancreatic tumour in mice models

09-Nov-2020

Key points from article :

N-LIfT (Neutrophil Only Leukocyte Infusion Therapy) has successfully infiltrated a transplanted pancreatic tumour in mice.

Pancreatic cancer is surrounded by a barrier of healthy cells making infiltration difficult.

Chimeric antigen receptor T cell therapy (CAR-T) has been successful in treating blood cancers but not solid tumours.

It finds and destroys cells with a specific marker on their surface.

"Solid tumours display a large degree of antigen heterogeneity and are constantly mutating. Targeting a few antigens is like developing a few keys when there are many ever changing locks." -Alex Blyth, CEO

N-LIfT unlike CAR-T deliberately avoids targeting specific molecules and instead engages the immune system against cancer.

It is produced from stem cells of exceptional cancer killing donors.

These stem cells proliferate into billions of neutrophils that infiltrate and destroy cancer cells.

Research by LIfT BioSciences.

N-LIfT is an allogenic cell therapy which recruits patient's own immune cells against cancers

Mentioned in this article:

Tap on icon for description, click on resource name for more details.

Company Representative

Founder and Chief Executive Officer of LIfT BioSciences.

Company

Biotechnology company that develops a portfolio of potentially life-saving immuno-oncology cell therapies